Literature DB >> 12487508

New guidelines for the management of migraine in primary care.

A J Dowson1, S Lipscombe, J Sender, T Rees, D Watson.   

Abstract

Despite repeated initiatives over the past decade, migraine remains under-recognised, under-diagnosed and under-treated in everyday clinical practice. The Migraine in Primary Care Advisors (MIPCA) group has produced new guidelines for migraine management to attempt to rectify this situation. MIPCA is a group of physicians, nurses, pharmacists and other healthcare professionals dedicated to the improvement of headache management in primary care, who have also worked closely with the Migraine Action Association (the UK patients' group) in the development of these guidelines. The principles of the new MIPCA guidelines are: To arrange specific consultations for headache. To institute a system of detailed history taking, patient education and buy-in at the outset of the consultation. To utilise a new screening algorithm for the differential diagnosis of headache, which can be confirmed by further questioning, if necessary. To institute a process of management that is individualised for each patient, using a new algorithm. Assessing the impact on the patient's daily life is a key aspect of diagnosis and management. To prescribe only treatments that have objective evidence of favourable efficacy and tolerability. To utilise prospective follow-up procedures to monitor the success of treatment. To organise a team approach to headache management in primary care.

Entities:  

Mesh:

Year:  2002        PMID: 12487508     DOI: 10.1185/030079902125001164

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  19 in total

Review 1.  Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Authors:  Andrew J Dowson; David W Dodick; Volker Limmroth
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  A qualitative study of migraine involving patient researchers.

Authors:  Judith Belam; Gill Harris; David Kernick; Frances Kline; Krissy Lindley; Jayne McWatt; Annie Mitchell; Debbie Reinhold
Journal:  Br J Gen Pract       Date:  2005-02       Impact factor: 5.386

Review 3.  Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates.

Authors:  Frederick R Taylor; Robert G Kaniecki
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 5.  Migraine headache: options for acute treatment.

Authors:  Frederick R Taylor
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

6.  New uses of the Migraine Screen Questionnaire (MS-Q): validation in the Primary Care setting and ability to detect hidden migraine. MS-Q in Primary Care.

Authors:  Miguel J Láinez; Jesús Castillo; Manuel Domínguez; Gemma Palacios; Silvia Díaz; Javier Rejas
Journal:  BMC Neurol       Date:  2010-06-08       Impact factor: 2.474

7.  Preventive pharmacologic treatments for episodic migraine in adults.

Authors:  Tatyana A Shamliyan; Jae-Young Choi; Rema Ramakrishnan; Jennifer Biggs Miller; Shi-Yi Wang; Frederick R Taylor; Robert L Kane
Journal:  J Gen Intern Med       Date:  2013-04-17       Impact factor: 5.128

8.  A case of chronic migraine remission after chiropractic care.

Authors:  Peter J Tuchin
Journal:  J Chiropr Med       Date:  2008-06

9.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

10.  Preliminary results, methodological considerations and recruitment difficulties of a randomised clinical trial comparing two treatment regimens for patients with headache and neck pain.

Authors:  Willem De Hertogh; Peter Vaes; Dirk Devroey; Paul Louis; Hans Carpay; Steven Truijen; William Duquet; Rob Oostendorp
Journal:  BMC Musculoskelet Disord       Date:  2009-09-23       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.